|
Daily |
3 times a week | |||
|
By weight |
Maximum (mg) |
By weight |
Maximum (mg) | |
|
First-line drugs | ||||
|
Isoniazid |
5 mg/kg |
300 |
10 mg/kg |
600 |
|
Rifampin |
10 mg/kg |
600 |
10 mg/kg |
600 |
|
Pyrazinamide |
20-25 mg/kg |
2000 |
30-40 mg/kg |
4000 |
|
Ethambutol |
15-20 mg/kga |
1600 |
25-40 mg/kg |
2400 |
|
Second-line drugs | ||||
|
Fluoroquinolonesb: Moxifloxacin |
400 |
d | ||
|
Fluoroquinolonesb: Levofloxacin |
750-1000 |
d | ||
|
Injectables: Amikacinc |
15 mg/kg as a single dosee |
|
d | |
|
a Optimal dosing is unclear. It is clear that eye toxicity is dose dependent, and its risk is higher at 25 mg/kg than at 15 mg/kg. b Gatifloxacin is not recommended in Canada because of dysglycemia problems. This drug has been used in recent trials and is still used in some countries. c Of the injectables, amikacin is preferred for use in Canada because of the ready availability of the drug, familiarity with its use by clinicians, nurses, and pharmacists, and the ability to measure serum drug concentration in many facilities. Streptomycin is not available in Canada but may be preferred in some low- and middle-income countries, as rates of toxicity are similar and costs may be lower. d There are inadequate data from randomized trials on the use of fluoroquinolones or injectables as part of intermittent regimens. If these drugs are needed because of intolerance or resistance to first-line drugs, daily therapy is suggested. e Initial dosage if renal function is normal. Dosing should be adjusted based on peak and trough serum levels in consultation with a pharmacist. | ||||
|
Source: ©All Rights Reserved. Canadian Tuberculosis Standards, 7th Edition. The Public Health Agency of Canada, The Lung Association, and the Canadian Thoracic Society, 2014. Adapted and reproduced with permission from the Minister of Health, 2016. | ||||